🎵 Self-selected music during chemo doesn’t help only patients - it also increases positive mood 😊 and reduces distress 😌 in caregivers. 🍀 🎶 💸 Low-cost ✅ ⚠️ Low-risk ✅ 🔝 High-impact ✅ Read more: 🔗 ascopubs.org/doi/10.1200/OP… OncoAlert #SupportiveCare 🎀 Journal of Clinical Oncology

🆕 in JAMA Oncology :💣 The U-BOMB Phase 2 Non-RCT: Utidelone ➕ Bevacizumab for ERBB2-negative #MetastaticBreastCancer 🎀with active #BrainMetastases 🧠 👩 N=47 ✅ CNS ORR: 42.6% 📊 Median PFS: 7.7 months ⚠️ Manageable toxicity 🔗jamanetwork.com/journals/jamao… OncoAlert

Truly a #legacy podcast for me as this was the last conversation I had with my dear #mentor and #hpm friend the late Dr John Mulder. Grateful he let me share my heart for #pallonc #supponc and #survonc. More poignant it comes on the heels of our #paper 🍎:

#AIinMedicine In a study of 362 #BreastCancer cases, ChatGPT 🤖 matched expert consensus in 46%, with only 39% response consistency ⚠️Lower accuracy in stage IV, molecular/genetic & #ADC cases ⚠️ 68% varied in detail & format 🔗 ascopubs.org/doi/10.1200/CC… OncoAlert Journal of Clinical Oncology

Excited to head out this week to share the #BestofASCO in #pallonc and #supponc later this week. Join us! x.com/realbowtiedoc/… ASCO Cardinale B. Smith Christine Parseghian, MD Katrina Pedersen, MD, MS Brittany Knick Ragon, MD Julia McGuinness, MD, MS Jim Smithy Sheena Bhalla Ana I. Velázquez Mañana, MD, MSc, FASCO Walter Stadler Hiba Khan MD MPH

#Immunotherapy in #GynOnc 🍀 Nivolumab ➕ ipilimumab in advanced gynecological clear cell cancers (CCCs ) (MoST‑CIRCUIT phase 2 nonRCT) 👇 👩‍🦰 N=28 |⏳mFU 11.2 months ✅ ORR 54% ✅ 6‑mo PFS 58% ✅ mDOR & mOS not reached 🔗 jamanetwork.com/journals/jamao… OncoAlert JAMA Oncology

#SupportiveCare in #BreastCancer 🎀 🌸 #Elinzanetant, a neurokinin-targeted therapy, significantly reduced vasomotor symptoms in women with #BC on endocrine therapy 👇 🔗 nejm.org/doi/full/10.10… OncoAlert NEJM

✨ This week’s #JournalClub by OncoAlert & VJ Oncology brings us 🇮🇹 Icro Meattini discussing Multimodal De-Escalation in Early #BreastCancer 🎀, on the ASCO Educational Book 📘 Link to publication: 👇 🔗 ascopubs.org/doi/10.1200/ED…

🆕 in The Lancet Oncology : In the STAMPEDE phase 3 trial, metformin in non-diabetic 👨with metastatic hormone-sensitive #ProstateCancer starting #ADT showed: ❌ no OS benefit (67.4 vs. 61.8 mo; HR 0.91) ✅ ↓ metabolic effects of ADT ⚠️ ↑ GI AEs gr ≥3 🔗 sciencedirect.com/science/articl…

💡 Very important overview of side effects of new and emerging #BreastCancer 🎀 therapies 💊 💉 in the ASCO Educational Book 📚 ✨ 🔗 ascopubs.org/doi/10.1200/ED… OncoAlert #Toxicity #EndocrineTherapy #TargetedAgents

Phase 2 trial in pretreated recurrent/metastatic #CervicalCancer shows camrelizumab + famitinib improves outcomes 🆚 camrelizumab alone or chemo 🎯 ORR: 41.0% 🆚 24.1% 🆚 14.3% ⏱️ PFS: 8.1 🆚 4.1 🆚 2.9 mo 💥 OS: 20.2 🆚 14.9 🆚 13.9 mo 🔗 ascopubs.org/doi/abs/10.120… OncoAlert

🧴 Prophylactic skincare (MD meds + pharmacist education + nurse-led care) in NSCLC pts on #Nivo + #Ipi ± chemo led to ↓ skin toxicities (21%➡8%), ↓ steroid use (36%➡10%), ↓ discontinuation (21%➡4%). 🔗 ascopubs.org/doi/10.1200/OP… OncoAlert #SupportiveCare #Immunotherapy

🧠 Always informed with the OncoAlert 🚨 Weekly Round Up | This week in #BreastCancer 🎀: ✅ PRIM-B: Prognostic ctDNA model in metastatic disease ✅ Breastfeeding after BC in young #BRCA🧬 carriers – new insights 🔗 Stay updated: OncoAlert360.com

Key #Oncology 🆙dates with🚨 The OncoAlert 🚨 WEEKLY RoundUp 💫 Register 👉 OncoAlert360.com 📌 Highlight this week: ✅ POSITIVE Trial in #BreastCancer ✅ Geriatric Assessment ✅ Molecular insights & mutagenic forces in solid tumors ✅ TALAPRO2, ACCORD & more

🚨 The OncoAlert WEEKLY RoundUp (July 25-31, 2025) 📨 Register 👉 OncoAlert360.com 💫 #BreastCancer 🎀 highlights: ✅ Biomarkers of response and resistance to immune check point inhibitors ✅ POETIC Trial & more .. ✨🌟

🚨 THE #OncoAlert5k at #ESMO25 🏃‍♀️🏃‍♂️ 📅 Saturday, October 18, 2025 – 7 AM 📍 Starting at the iconic Brandenburg Gate, Berlin 🇩🇪 Sign up coming soon – don’t miss it! 🏁✨

💡 Economic evaluation suggests risk-reducing mastectomy (RRM) may be cost-effective for women aged 30–55 with ≥35% lifetime #breastcancer risk, even without BRCA1/2/PALB2 mutations. 💡Potential to prevent ~11% of annual #BC cases in the UK 🇬🇧. 🔗 buff.ly/ooyzfs1

Alpelisib +Olaparib in platinum-resistant/refractory #HGSOC without BRCA mutations: ❌ not improve PFS 🆚 chemo (3.6 🆚3.9 mo) ❌ No OS/ORR benefit Exploratory biomarkers 👉 possible responder subgroups. 🔗 buff.ly/7hxlVtv

Top #BreastCancer Oncologists for July 2025, curated by LARVOL CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | Paolo Tarantino | Yakup Ergün

🚨 Phase II trial in #SCLC & 1–10 brain mets: 🧠 SRS/SRT showed low neurologic death (11%) 🆚 historical WBRT (17.5%), with only 22% needing salvage WBRT. Supports SRS/SRT as a viable, less toxic WBRT alternative. 💡 Read more: ascopubs.org/doi/10.1200/JC…